{"id":416841,"date":"2021-01-19T09:03:35","date_gmt":"2021-01-19T14:03:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416841"},"modified":"2021-01-19T09:03:35","modified_gmt":"2021-01-19T14:03:35","slug":"sirtex-medical-announces-collaboration-update-with-oncosec-medical","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/","title":{"rendered":"Sirtex Medical announces collaboration update with OncoSec Medical"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Collaboration provides Sirtex the right to co-promote OncoSec lead product candidate<\/i>
\n \u00a0TAVO\u2122 for the treatment of advanced melanoma<\/i>\n <\/p>\n

\n WOBURN, Mass.<\/span>, Jan. 19, 2021<\/span> \/PRNewswire\/ — Sirtex Medical US Holdings, Inc.<\/a><\/u> (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec’s lead product candidate TAVO\u2122<\/span> (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Sirtex
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO\u2122<\/span> and its related EP gene delivery system in the United States<\/span> in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.\u00a0 <\/p>\n

TAVO\u2122<\/span> is DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.\u00a0TAVO\u2122<\/span> is administered directly into the tumor using OncoSec’s proprietary EP gene delivery system, which employs a series of momentary energy pulses.\u00a0Those pulses are designed to increase the permeability of the cell membrane and facilitate uptake of IL-12 coded DNA into the tumor cells.\u00a0TAVO\u2122<\/span> is a potential treatment for multiple cancer indications as a monotherapy or in combination with leading checkpoint inhibitors. Currently, TAVO\u2122<\/span> is in its pivotal clinical trial for advanced melanoma (KEYNOTE-695).<\/p>\n

“We are thrilled to advance our partnership with OncoSec as the clinical development of TAVO\u2122<\/span> progresses,” said Kevin R. Smith<\/span>, Chief Executive Officer of Sirtex. “OncoSec is committed to bringing much-needed treatment options to patients with cancer, and we are excited to continue supporting them in that journey.”<\/p>\n

This agreement further extends the existing collaboration between Sirtex and OncoSec.\u00a0Last year, Sirtex acquired an equity stake in OncoSec and entered an arrangement to assist OncoSec with pre-marketing activities for TAVO\u2122<\/span> and its Visceral Lesion Applicator (VLA) product in exchange for a low single-digit royalty.\u00a0More details of the transaction documents can be found in OncoSec’s filings with the U.S. Securities and Exchange Commission.<\/p>\n

“Our collaboration with Sirtex is a natural fit given our common mission to deliver more effective therapies to patients,” said Daniel J. O’Connor<\/span>, CEO of OncoSec. “We are thankful for Sirtex’s continued support as we advance our TAVO\u2122<\/span> clinical program and diligently work to bring this treatment option to market.”<\/p>\n

\n About Sirtex
<\/b>Sirtex is a global healthcare business with offices in the U.S., Australia<\/span>, Europe<\/span> and Asia<\/span>, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres\u00ae<\/sup>Y-90<\/span> resin microspheres. For more information, visit www.sirtex.com<\/a><\/u>. SIR-Spheres\u00ae is a registered trademark of Sirtex SIR-Spheres Pty Ltd.<\/p>\n

APM-AP-003-01-21<\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/sirtex-medical-announces-collaboration-update-with-oncosec-medical-301210378.html<\/a><\/p>\n

SOURCE Sirtex<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Collaboration provides Sirtex the right to co-promote OncoSec lead product candidate \u00a0TAVO\u2122 for the treatment of advanced melanoma WOBURN, Mass., Jan. 19, 2021 \/PRNewswire\/ — Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec’s lead product candidate TAVO\u2122 (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system. The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO\u2122 and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days … <\/p>\n

Continue reading “Sirtex Medical announces collaboration update with OncoSec Medical”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416841","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSirtex Medical announces collaboration update with OncoSec Medical - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirtex Medical announces collaboration update with OncoSec Medical - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Collaboration provides Sirtex the right to co-promote OncoSec lead product candidate \u00a0TAVO\u2122 for the treatment of advanced melanoma WOBURN, Mass., Jan. 19, 2021 \/PRNewswire\/ — Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec’s lead product candidate TAVO\u2122 (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system. The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO\u2122 and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days … Continue reading "Sirtex Medical announces collaboration update with OncoSec Medical"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T14:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/926923\/Sirtex_Medical_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sirtex Medical announces collaboration update with OncoSec Medical\",\"datePublished\":\"2021-01-19T14:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/\"},\"wordCount\":472,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926923\\\/Sirtex_Medical_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/\",\"name\":\"Sirtex Medical announces collaboration update with OncoSec Medical - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926923\\\/Sirtex_Medical_Logo.jpg\",\"datePublished\":\"2021-01-19T14:03:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926923\\\/Sirtex_Medical_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926923\\\/Sirtex_Medical_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirtex Medical announces collaboration update with OncoSec Medical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sirtex Medical announces collaboration update with OncoSec Medical - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/","og_locale":"en_US","og_type":"article","og_title":"Sirtex Medical announces collaboration update with OncoSec Medical - Market Newsdesk","og_description":"PR Newswire Collaboration provides Sirtex the right to co-promote OncoSec lead product candidate \u00a0TAVO\u2122 for the treatment of advanced melanoma WOBURN, Mass., Jan. 19, 2021 \/PRNewswire\/ — Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec’s lead product candidate TAVO\u2122 (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system. The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO\u2122 and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days … Continue reading \"Sirtex Medical announces collaboration update with OncoSec Medical\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T14:03:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/926923\/Sirtex_Medical_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sirtex Medical announces collaboration update with OncoSec Medical","datePublished":"2021-01-19T14:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/"},"wordCount":472,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/926923\/Sirtex_Medical_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/","name":"Sirtex Medical announces collaboration update with OncoSec Medical - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/926923\/Sirtex_Medical_Logo.jpg","datePublished":"2021-01-19T14:03:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/926923\/Sirtex_Medical_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/926923\/Sirtex_Medical_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sirtex-medical-announces-collaboration-update-with-oncosec-medical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sirtex Medical announces collaboration update with OncoSec Medical"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416841"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416841\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}